Emerging therapies for multiple myeloma - PubMed (original) (raw)
Review
. 2009 Apr 30;23(5):407-15.
Affiliations
- PMID: 19476273
Free article
Review
Emerging therapies for multiple myeloma
David Dingli et al. Oncology (Williston Park). 2009.
Free article
Abstract
In the past decade, the therapeutic landscape for myeloma has changed dramatically with the advent of novel agents such as immunomodulatory drugs (IMiDs) and proteasome inhibitors (bortezomib). These agents alone have activity against myeloma with even better responses when combined with additional agents such as steroids and chemotherapy. Initially introduced for relapsed/refractory disease, these agents are being increasingly tested in the upfront setting with improvement in response rates and prolongation of responses. We review the key findings from recently completed and ongoing studies that evaluate the effect of the novel therapies, both in newly diagnosed myeloma and in relapsed disease. The use of these agents in specific settings is also discussed.
Comment in
- Maximizing the clinical benefit of novel therapies in multiple myeloma.
Laubach J, Mitsiades C, Anderson K, Richardson P. Laubach J, et al. Oncology (Williston Park). 2009 Apr 30;23(5):415-6, 419. Oncology (Williston Park). 2009. PMID: 19476274 Review. No abstract available. - Treatment of multiple myeloma: whence truth over belief?
Kaufman J, Lonial S. Kaufman J, et al. Oncology (Williston Park). 2009 Apr 30;23(5):420, 423. Oncology (Williston Park). 2009. PMID: 19476275 Review. No abstract available.
Similar articles
- Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
Siegel DS, Vij R, Jakubowiak AJ. Siegel DS, et al. Clin Adv Hematol Oncol. 2011 Apr;9(4):1-15. Clin Adv Hematol Oncol. 2011. PMID: 21928467 - Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A, Attal M, Roussel M. Palumbo A, et al. Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Clin Cancer Res. 2011. PMID: 21411441 Review. - How best to use new therapies in multiple myeloma.
Dingli D, Rajkumar SV. Dingli D, et al. Blood Rev. 2010 May;24(3):91-100. doi: 10.1016/j.blre.2010.03.001. Epub 2010 Apr 1. Blood Rev. 2010. PMID: 20359801 Free PMC article. Review. - [Triplets therapy for the patients of multiple myeloma].
Ishida T. Ishida T. Nihon Rinsho. 2013 Sep;71(9):1691-6. Nihon Rinsho. 2013. PMID: 24205736 Review. Japanese. - Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
Richardson PG, Laubach J, Mitsiades C, Schlossman RL, Doss D, Colson K, McKenney ML, Noonan K, Warren DL, Ghobrial IM, Munshi NC, Anderson K. Richardson PG, et al. Oncology (Williston Park). 2010 Mar;24(3 Suppl 2):22-9. Oncology (Williston Park). 2010. PMID: 20518367
Cited by
- Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.
Liu C, Russell SJ, Peng KW. Liu C, et al. Mol Ther. 2010 Jun;18(6):1155-64. doi: 10.1038/mt.2010.43. Epub 2010 Mar 16. Mol Ther. 2010. PMID: 20234340 Free PMC article. - Public goods in relation to competition, cooperation, and spite.
Levin SA. Levin SA. Proc Natl Acad Sci U S A. 2014 Jul 22;111 Suppl 3(Suppl 3):10838-45. doi: 10.1073/pnas.1400830111. Epub 2014 Jul 14. Proc Natl Acad Sci U S A. 2014. PMID: 25024192 Free PMC article. - The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy.
Lin Y, Bai L, Chen W, Xu S. Lin Y, et al. Expert Opin Ther Targets. 2010 Jan;14(1):45-55. doi: 10.1517/14728220903431069. Expert Opin Ther Targets. 2010. PMID: 20001209 Free PMC article. Review. - Differential impact of classical and non-canonical NF-κB pathway-related gene expression on the survival of breast cancer patients.
Espinoza-Sánchez NA, Győrffy B, Fuentes-Pananá EM, Götte M. Espinoza-Sánchez NA, et al. J Cancer. 2019 Aug 28;10(21):5191-5211. doi: 10.7150/jca.34302. eCollection 2019. J Cancer. 2019. PMID: 31602271 Free PMC article. - Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.
Ambrosini G, Do C, Tycko B, Realubit RB, Karan C, Musi E, Carvajal RD, Chua V, Aplin AE, Schwartz GK. Ambrosini G, et al. Cancer Res. 2019 May 1;79(9):2415-2425. doi: 10.1158/0008-5472.CAN-18-3177. Epub 2019 Mar 18. Cancer Res. 2019. PMID: 30885979 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous